Trials / Completed
CompletedNCT00927758
Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To examine the post-dose changes in exhaled Nitric Oxide (eNO) following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg | fluticasone propionate/salmeterol diskus |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2009-06-25
- Last updated
- 2017-03-29
- Results posted
- 2014-09-08
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00927758. Inclusion in this directory is not an endorsement.